Werewolf Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $16.4 million, a slight improvement from a net loss of $16.7 million in the same period last year. The company did not generate any revenue during the quarter, compared to $1.9 million in collaboration revenue for the third quarter of 2024. This decline in revenue is attributed to the execution of a transfer agreement with Jazz Pharmaceuticals in June 2024, which concluded Werewolf's material performance obligations under their collaboration agreement, resulting in no further revenue recognition.
Total operating expenses for the third quarter decreased to $15.7 million from $17.1 million in the prior year, primarily due to reduced research and development costs, which fell from $12.5 million to $11.6 million. The decrease in R&D expenses was driven by lower manufacturing costs associated with the WTX-330 program, which had higher costs in the previous year as it prepared for a Phase 1b/2 clinical trial. General and administrative expenses also decreased from $4.6 million to $4.1 million, reflecting lower personnel and professional service costs.
As of September 30, 2025, Werewolf Therapeutics had cash and cash equivalents of $65.7 million, down from $111.0 million at the end of 2024. The company’s total liabilities stood at $50.0 million, with a significant portion attributed to a term loan agreement with K2 HealthVentures. The company has expressed substantial doubt about its ability to continue as a going concern for at least the next twelve months, emphasizing the need for additional funding to support ongoing operations and clinical development.
In terms of operational developments, Werewolf is advancing its clinical trials for its lead product candidates, WTX-124 and WTX-330. The company is currently evaluating WTX-124 in a Phase 1/1b trial and has initiated a Phase 1b/2 trial for WTX-330. The company plans to release interim data from these trials in the fourth quarter of 2025. Additionally, Werewolf is focused on expanding its PREDATOR platform, which aims to develop innovative therapeutics for cancer and other immune-mediated conditions.
Looking ahead, Werewolf Therapeutics is actively seeking to raise additional capital through public equity offerings, collaborations, or other financing methods to sustain its operations and continue its product development efforts. The company acknowledges the uncertainty surrounding its ability to secure necessary funding and the potential impact on its business operations and growth trajectory.
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics is a biopharmaceutical company developing innovative immunotherapies for cancer and immune-mediated diseases. Using its proprietary PREDATOR platform, it engineers conditionally activated cytokine molecules (INDUKINE) that target the tumor microenvironment, aiming to enhance efficacy while minimizing toxicity. Its pipeline includes cytokine-based therapeutics like IL-2, IL-12, IL-21, IL-18, and IL-10, designed for systemic delivery and tumor-specific activation. The company focuses on immuno-oncology, autoimmune, and inflammatory disease treatments.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.